Allergy Therapeutics plc
AGYTF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $75,564 | $55,199 | $59,587 | $72,768 |
| % Growth | 36.9% | -7.4% | -18.1% | – |
| Cost of Goods Sold | $41,066 | $25,462 | $26,342 | $23,262 |
| Gross Profit | $34,498 | $29,737 | $33,245 | $49,506 |
| % Margin | 45.7% | 53.9% | 55.8% | 68% |
| R&D Expenses | $15,377 | $22,900 | $20,121 | $15,659 |
| G&A Expenses | $19,086 | $22,790 | $25,179 | $20,828 |
| SG&A Expenses | $38,288 | $42,381 | $48,884 | $46,832 |
| Sales & Mktg Exp. | $19,202 | $19,591 | $23,705 | $26,004 |
| Other Operating Expenses | $21,338 | -$287 | $3,894 | -$740 |
| Operating Expenses | $75,003 | $64,994 | $72,899 | $61,751 |
| Operating Income | -$28,162 | -$35,257 | -$39,654 | -$12,245 |
| % Margin | -37.3% | -63.9% | -66.5% | -16.8% |
| Other Income/Exp. Net | -$11,038 | -$3,909 | -$2,112 | -$412 |
| Pre-Tax Income | -$39,200 | -$39,166 | -$41,766 | -$12,657 |
| Tax Expense | $932 | $1,050 | $1,305 | $1,119 |
| Net Income | -$55,093 | -$40,216 | -$43,071 | -$13,776 |
| % Margin | -72.9% | -72.9% | -72.3% | -18.9% |
| EPS | -0.008 | -0.011 | -0.038 | -0.012 |
| % Growth | 21.5% | 71.5% | -213.3% | – |
| EPS Diluted | -0.008 | -0.011 | -0.038 | -0.012 |
| Weighted Avg Shares Out | 4,766,440 | 3,743,332 | 1,456,288 | 1,396,840 |
| Weighted Avg Shares Out Dil | 4,766,440 | 3,743,332 | 1,456,288 | 1,396,840 |
| Supplemental Information | – | – | – | – |
| Interest Income | $382 | $285 | $329 | $257 |
| Interest Expense | $6,693 | $4,107 | $2,441 | $669 |
| Depreciation & Amortization | $5,727 | $4,319 | $4,224 | $4,166 |
| EBITDA | -$40,400 | -$30,740 | -$35,101 | -$7,822 |
| % Margin | -53.5% | -55.7% | -58.9% | -10.7% |